Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the best dose and side effects of sorafenib tosylate and
nivolumab in treating patients with liver cancer that cannot be removed by surgery
(unresectable), has spread to nearby tissues or lymph nodes (locally advanced) or to other
places in the body (metastatic). Sorafenib tosylate may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving sorafenib tosylate and
nivolumab may work better in treating patients with liver cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Robin Kate Kelley University of California, San Francisco